Daniel G. Email & Phone Number

• Start-up Pre-Clinical Development and Diagnostics company with successful Series A round
• Establishing budgets, cash runway, financial review of operations, preparing and presenting board materials
• Evaluating lease options, capital equipment acquisition, in-house / outsource options, ramp-up
• Supporting efforts to identify and expand new lines of business, monetization options

• Emerging growth company leveraging Visual AI and Machine Learning in the medical device market
• Implement and manage budgeting, forecasting and multi-year planning processes.
• Evaluate and quantify sales contracts, service level agreements, including terms and pricing.
• Collaborate on strategy for expanding product offerings including SaaS models and subscriptions.
• Prepare board materials, analyze corporate development options (M&A, JV), equity fundraising activities with VCs.

San Diego, California, US

• SVP, Global Corporate Finance (9/2022 – 11/2023)VP of Corporate Finance / Business Development (10/2021 – 9/2022)Privately held, development-stage Global Biopharma enterprise evaluating, in-licensing, and developing.
• Established and managed new finance function, was responsible for budgeting, forecasting, analysis, strategic planning and business development support.
• Modelled a comprehensive corporate planning and valuation file, provided critical insights for strategic decision-making and investment opportunities.
• Collaborated with business development by providing financial expertise and guidance during term sheet negotiations, market sizing, and ROI calculations.
• Managed a team of 10 finance professionals, including the Corporate Controller and Director of Finance.
• Achieved cost savings of 10% of operating expenses, implemented efficient financial controls and vendor management process.

San Diego, CA, US

• VP, Corporate Finance - 1/2020 - 9/2021Senior Director of Finance - 1/2019 - 1/2020Director of Finance - 2/2017 - 12/2018Formerly Progenity, IncSpecialized Genetic Testing and Diagnostics
• Hands on development and execution of corporate strategy, resulting in significant growth from a private / pre-IPO enterprise to public company status in June 2020.
• Designed and executed department infrastructure to move from basic reporting to best-in-class business analytics and actionable management reporting, while keeping pace with the immediate needs of a highly complex and.
• Sourced and onboarded team from 3 analysts to 12 team members in both San Diego and Dallas locations to support corporate needs, focused on FP&A, Business Analytics, and Sales Support / Sales Analytics; Resulted in.
• Created sophisticated and flexible financial models to facilitate detailed discussions between executive team, investors, and bankers. Ongoing projects included M&A opportunity review, SOX/Controls, ASC606 and Revenue.

Arlington, VA, US

• Formerly New Century Health - Acquired
• Built department infrastructure and analytic capability from scratch, including budgeting, forecasting, and reporting processes and deliverables. Reduced budget process by 4 months.
• Hired and mentored both accounting and finance staff, successfully transitioned processes to existing staff, collaboratively worked with all departments to manage operating cash flow.
• Met objectives at New Century Health to establish effective budgeting, forecasting, reporting, and analytical processes. With those objectives completed and the company poised to succeed, I transitioned from New.

Dublin, OH, US

• Director, Finance - 3/2015 – 4/2016Senior Manager, Finance - 6/2013 – 2/2015Formerly RainTree Oncology Services - Acquired
• Prepared financial projections and analytics (including M&A and JV due diligence), valuations, data room management, due diligence (outside counsel, bankers, auditors) related to ~$100M sale of RainTree to Cardinal.
• Established and managed finance department processes, created advanced budgeting and forecasting models, monthly and quarterly operational reports, and financial dashboards.
• Financial point person for the research, implementation, and growth of new sources of revenue. Revenue growth of 72% CAGR during tenure.
• Worked with Executive Team on strategic projects, including securing external debt, HR planning, pharma compliance / contract support, and leveraging existing resources. Achieved 25% Opex efficiency.
• Responsible for all corporate presentations to the BOD, external investors, and banking communities. Included summarizing business models, strategic plans, financial projections, and recommendations.

Dublin, Coolock, IE

• Associate Director, Finance - 1/2012 – 6/2013Manager, Finance - 1/2010 – 12/2011Senior Analyst - 11/2007 – 12/2009Formerly Actavis Pharmaceuticals - Merger
• Calculated domestic sales allowances of more than $3.0 billion annually. Subsequent payment and balance sheet analysis consistently within 1% variance. Zero internal or external audit findings related to gross-to-net.
• Wholly responsible for all net sales management, financial reporting, and contract compliance for the launch of key authorized generic product which generated over $150 million in gross profit.
• Managed 20 separate domestic and international partner royalty agreements accounting for $585 million in annualized net revenue.
• ASP flux for approximately 1,000 products, prepared product line profitability reports. Additional duties included SOX and internal audit controls testing, coordinating with external auditors.

Master Of Business Administration (Mba), Finance & Strategic Planning

Bachelor Of Arts (B.A.)